Login / Signup

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study.

Christian SchwabeChris WynneDayaker Reddy DyapaArpitkumar PrajapatiDisha Dadke
Published in: Oncology and therapy (2024)
ANZCTR number: ACTRN12621000573853.
Keyphrases
  • double blind
  • placebo controlled
  • open label
  • clinical trial
  • epidermal growth factor receptor
  • phase iii
  • phase ii
  • metastatic breast cancer
  • study protocol
  • young adults
  • tyrosine kinase